|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle显示文摘鼠科的骨胳的肌肉包含造血的干细胞,而是这个潜力到目前为止没被学习份量上或品质上试管内。确定造血的干细胞潜力,我们在 long-termculture 开始使用了高度净化的 SP/CD45 (+) 房间房间(LTC-IC ) 试金。从鼠科的肌肉净化的 SP/CD45 (+) 房间人口被发现从肌肉与 1/640 .Single-cell-sorted SP/CD45 (+) 房间的 LTC-IC 频率举办重要干细胞活动在白天 16 点的展出柔韧的 proliferative 活动试管内(380 褶层扩大) ,特别在有 OP-9 层的文化以后,那也支持胚胎的干细胞。放大房间人口与 myeloid 的证据从单个房间 exhibitedmultilineage 区别能力发源,淋巴并且 NK 房间标记。因此,我们的结果证明能被 LTC-IC 试金确定的造血的干细胞第一次也在鼠科的骨胳的肌肉和表演存在,在单个房间的水平,这些房间展出多行的年龄区别能力和主要 proliferative 潜力。 | Celine Haond Frangoise Farace Martine Guillier Yann Lecluse Frederic Mazurier William Vainchenker Ali G Turhan | 2007 | Cell Research2007，17，9： | 4 |
| 2 | myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strat- egies显示文摘 | Tefferi A Vainchenker W | 2011 | J Clin Oncol2011，29，5： | 1 |
| 3 | Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? 显示文摘 | Constantinescu SN Vainchenker W | 2012 | Hematology Am Soc Hematol Educ Program2012，2012，： | 1 |
| 4 | c-mpl, the thrombo-poietin receptor显示文摘 | Vainchenker W Methia N Debili N | 1995 | Thromb Haemost1995，74，1： | 1 |
| 5 | Ohgodeoxynucleotides antisense to the proto- oncogen c- mpl ligand显示文摘 | Methia N Louache F Vainchenker W | 1993 | Blood1993，82，5： | 1 |
| 6 | Distinct localizations and roles of non‐muscle myosin II during proplatelet formation and platelet release显示文摘 | I. Badirou J. Pan S. Souquere C. Legrand G. Pierron A. Wang A. Eckly A. Roy C. Gachet W. Vainchenker Y. Chang C. Léon | 2015 | J Thromb Haemost2015，，： | 1 |
| 7 | A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases显示文摘 | Vainchenker W Constantinescu SN | 2005 | Hematology Am Soc Hematol Educ Program2005，1，： | 1 |
| 8 | Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies显示文摘 | Sabri S Zelenika D Deutsch E Frascogna V Klijanienko J Vainchenker W Joab I Bourhis J | 2003 | Oncogene2003，22，15： | 1 |
| 9 | JAK/STAT signaling in hematological malignancies显示文摘 | Vainchenker W Constantinescu SN | 2013 | Oncogene2013，32，： | 1 |
| 10 | Effects of the recombi-nant hematopoietic growth factors interleukin-3,interleukin-6,stem cell factor,and leukemia in-hibitory factor on the megakaryocytic differentia-tion of CD34+ cells显示文摘 | Debili N Masse JM Katz A Guichard J Breton-Gorius J Vainchenker W | 1993 | Blood1993，8495，： | 1 |
| 11 | Defective endcxnitosisduring megakaryopoiesis leads to thrombocytopenia in Fanca-/_ mice显示文摘 | Pawlikowska P Fouchet P Vainchenker W | 2014 | Blood2014，124，24： | 1 |
| 12 | Identification of lymphomyeloid primitive progenitor cells in fresh human cord blood and in the marrow of nonobese diabeticsevere combined immunodeficient (NOD-SCID) mice transplanted with human CD34(+) cord blood cells显示文摘 | Pflumio F Vainchenker W | 1999 | J Exp Med1999，189，10： | 1 |
| 13 | Mechanisms of WASp-mediated hematologic and immunologic disease显示文摘 | Burns S Cory GO Vainchenker W | 2004 | Blood2004，104，： | 1 |
| 14 | Thrombopoietin and its receptor 显示文摘 | Wendling F Vainchenker W | 1998 | Eur Cytokine Netw1998，9，3： | 1 |
| 15 | Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies 显示文摘 | Tefferi A Vainchenker W | 2011 | J Clin Oncol2011，29，5： | 1 |
| 16 | Myeloproliferative neoplasms : molecular pathophysiology, essential clinical understanding, and treatment strategies 显示文摘 | Tefferi A Vainchenker W | 2011 | J Clin Onco12011，29，： | 1 |
| 17 | Oligodeoxynucleotides antisense to the proto-oncogene c-MPLspecifically inhibit in vitro megakaryocytopoiesis 显示文摘 | Methia N Louache F Vainchenker W | 1993 | Blood1993，82，5： | 1 |
| 18 | Mechanisms of WASp-mediated hematologic and immunologic disease显示文摘 | Burns S Cory GO Vainchenker W | 2004 | Blood2004，104，12： | 1 |
| 19 | A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases显示文摘 | VAINCHENKER W CONSTANTINESCU S N | 2005 | Hematology Am Soc Hematol Educ Program2005，1，： | 1 |
| 20 | JAKs in pathology:role of janus kinases in hematopoietic malignancies and immunodeficiencies显示文摘 | VAINCHENKER W DUSA A CONSTANTINESCU S N | 2008 | Semin Cell Dev Biol2008，19，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员